Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Neuromuscular Junction And Blockade01:29

Neuromuscular Junction And Blockade

5.0K
The site of chemical communication between a motor neuron and a muscle fiber is called the neuromuscular junction (NMJ). The end of the motor neuron at the NMJ divides into a cluster of synaptic end bulbs. The cytoplasm of these bulbs consists of synaptic vesicles enclosing acetylcholine molecules, the principal neurotransmitter released at the NMJ. The region opposite the synaptic bulb that ends in the muscle fiber is called the motor end plate, which has acetylcholine receptors. Within the...
5.0K
Induced-fit Model01:13

Induced-fit Model

89.2K
Most chemical reactions in cells require enzymes—biological catalysts that speed up the reaction without being consumed or permanently changed. They reduce the activation energy needed to convert the reactants into products. Enzymes are proteins, that usually work by binding to a substrate—a reactant molecule that they act upon.
Enzymes exhibit substrate specificity, meaning that they can only bind to certain substrates. This is mainly determined by the shape and chemical...
89.2K
Inclusive Fitness00:57

Inclusive Fitness

41.2K
Most altruistic behavior—in which one animal helps another at a cost to themselves—occurs between relatives. Scientists think these altruistic behaviors evolved because they increase the inclusive fitness of the animal providing help.
41.2K
Goodness-of-Fit Test01:16

Goodness-of-Fit Test

9.2K
The goodness-of-fit test is a type of hypothesis test which determines whether the data "fits" a particular distribution. For example, one may suspect that some anonymous data may fit a binomial distribution. A chi-square test (meaning the distribution for the hypothesis test is chi-square) can be used to determine if there is a fit. The null and alternative hypotheses may be written in sentences or stated as equations or inequalities. The test statistic for a goodness-of-fit test is given as...
9.2K
PD Controller: Design01:26

PD Controller: Design

656
In automotive engineering, car suspension systems often employ Proportional Derivative (PD) controllers to enhance performance. PD controllers are utilized to adjust the damping force in response to road conditions. A controller, acting as an amplifier with a constant gain, demonstrates proportional control, with output directly mirroring input.
Designing a continuous-data controller requires selecting and linking components like adders and integrators, which are fundamental in Proportional,...
656
Time-Domain Interpretation of PD Control01:07

Time-Domain Interpretation of PD Control

407
Proportional-Derivative (PD) control is a widely used control method in various engineering systems to enhance stability and performance. In a system with only proportional control, common issues include high maximum overshoot and oscillation, observed in both the error signal and its rate of change. This behavior can be divided into three distinct phases: initial overshoot, subsequent undershoot, and gradual stabilization.
Consider the example of control of motor torque. Initially, a positive...
407

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Impact of prior CAR T-cell treatment on graft-vs-host disease and non-relapse mortality after allogeneic transplantation.

Transplantation and cellular therapy·2026
Same author

Outcomes of patients with relapsed or refractory classic Hodgkin lymphoma after frontline brentuximab vedotin.

Blood cancer journal·2026
Same author

Autologous transplant for patients with chemotherapy-sensitive late relapse of diffuse large B-cell lymphoma.

Blood neoplasia·2026
Same author

Prognostic factors and survival outcomes in relapsed/refractory aggressive B-cell lymphomas treated with epcoritamab.

Blood advances·2026
Same author

Outcomes of Hematopoietic Cell Transplantation in Patients with Plasmablastic Lymphoma.

Transplantation and cellular therapy·2026
Same author

Nivolumab in combination with AVD as frontline treatment for patients with classic Hodgkin lymphoma: A real-world analysis from 20 US centers.

HemaSphere·2026

Related Experiment Video

Updated: Feb 1, 2026

Author Spotlight: Magnetic Fluorescent Bead-Based Dual-Reporter Flow Analysis of PDL1-Vaxx Peptide Vaccine-Induced Antibody Blockade of the PD-1/PD-L1 Interaction
10:18

Author Spotlight: Magnetic Fluorescent Bead-Based Dual-Reporter Flow Analysis of PDL1-Vaxx Peptide Vaccine-Induced Antibody Blockade of the PD-1/PD-L1 Interaction

Published on: July 7, 2023

1.7K

Where does PD-1 blockade fit in HL therapy?

Alex F Herrera1

  • 1Department of Hematology and Hematopoietic Cell Transplantation, City of Hope National Medical Center, Duarte, CA.

Hematology. American Society of Hematology. Education Program
|December 4, 2018
PubMed
Summary

Programmed cell death-1 (PD-1) blockade is effective for relapsed or refractory classical Hodgkin lymphoma (HL). Continued PD-1 therapy and novel combinations are being explored to improve outcomes in HL patients.

More Related Videos

Identifying PD-1/PD-L1 Inhibitors with Surface Plasmon Resonance Technology
07:04

Identifying PD-1/PD-L1 Inhibitors with Surface Plasmon Resonance Technology

Published on: May 2, 2025

1.2K
Y-90 Radioembolization and PD-1 Inhibitor as Neoadjuvant Treatment in Hepatocellular Carcinoma
09:11

Y-90 Radioembolization and PD-1 Inhibitor as Neoadjuvant Treatment in Hepatocellular Carcinoma

Published on: May 24, 2024

1.2K

Related Experiment Videos

Last Updated: Feb 1, 2026

Author Spotlight: Magnetic Fluorescent Bead-Based Dual-Reporter Flow Analysis of PDL1-Vaxx Peptide Vaccine-Induced Antibody Blockade of the PD-1/PD-L1 Interaction
10:18

Author Spotlight: Magnetic Fluorescent Bead-Based Dual-Reporter Flow Analysis of PDL1-Vaxx Peptide Vaccine-Induced Antibody Blockade of the PD-1/PD-L1 Interaction

Published on: July 7, 2023

1.7K
Identifying PD-1/PD-L1 Inhibitors with Surface Plasmon Resonance Technology
07:04

Identifying PD-1/PD-L1 Inhibitors with Surface Plasmon Resonance Technology

Published on: May 2, 2025

1.2K
Y-90 Radioembolization and PD-1 Inhibitor as Neoadjuvant Treatment in Hepatocellular Carcinoma
09:11

Y-90 Radioembolization and PD-1 Inhibitor as Neoadjuvant Treatment in Hepatocellular Carcinoma

Published on: May 24, 2024

1.2K

Area of Science:

  • Oncology
  • Immunology
  • Genetics

Background:

  • Genetic alterations at the 9p24.1 locus drive PD-L1 expression in classical Hodgkin lymphoma (HL).
  • PD-L1 expression on tumor cells and in the microenvironment impairs host anti-tumor immune response.
  • This immune evasion makes HL a prime candidate for PD-1 blockade therapy.

Purpose of the Study:

  • To review the efficacy and evolving role of PD-1 blockade in classical Hodgkin lymphoma.
  • To discuss current and emerging treatment strategies involving PD-1 inhibitors in HL.

Main Methods:

  • Review of clinical trial data and published literature on PD-1 blockade in HL.
  • Analysis of response rates, duration of response, and safety profiles of anti-PD-1 therapies.
  • Evaluation of combination regimens and earlier treatment applications.

Main Results:

  • Anti-PD-1 antibody monotherapy shows significant efficacy in relapsed/refractory HL, with objective responses in about two-thirds of patients.
  • Median duration of response is substantial (16.6 months in one study), leading to FDA approvals for nivolumab and pembrolizumab.
  • Patients may benefit from continued PD-1 blockade beyond progression, and chemotherapy can re-induce response after PD-1 failure.

Conclusions:

  • PD-1 blockade is an established treatment for advanced relapsed/refractory HL.
  • Ongoing research is investigating novel combinations and earlier use of PD-1 inhibitors in HL treatment paradigms.
  • The future role of PD-1 blockade in HL will be shaped by ongoing studies and treatment landscape evolution.